Clinical trials
Hepatic Carcinoma clinical trials
Below are recruiting hepatic carcinoma clinical trials, each written for real people, not researchers. We’re tracking 51 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06888063RecruitingPhase 2
Chemo pump into the liver for bile duct cancer that can be surgically removed
This trial tests whether giving extra chemotherapy directly to the liver through a small pump (called HAIP) before or after surgery can improve outcomes for patients with bile duct cancer inside the liver. It is for patients whose cancer is considered removable by surgery.
Rotterdam, South HollandAges 18 years+ - NCT05484908Recruiting
Tested treatment for hepatitis B-related liver cancer after immunotherapy
This trial studies whether the ALSS treatment is safe and effective for people with hepatitis B-related hepatocellular carcinoma who recently received immune checkpoint inhibitors. It may help improve outcomes for certain liver-related complications after immunotherapy, based on how their liver tests look.
Guangzhou, GuangdongAges 18–65 - NCT07557251RecruitingPhase 1
Combination immunotherapy for advanced liver cancer with hepatitis B
This trial tests a new combination of three drugs (BRII-5395, sintilimab, and bevacizumab) for advanced hepatocellular carcinoma (liver cancer) in patients with hepatitis B who have not responded well to previous treatments. The goal is to evaluate whether this combination is safe and effective.
BeijingAges 18–70 - NCT07727759Recruiting
CT scan to predict liver failure after surgery
This trial uses special CT scans to create a map of your liver's blood vessels before surgery. The goal is to predict if your liver might fail after part of it is removed, so doctors can better plan your care.
Minya, Minya GovernorateAges 18 years+ - NCT06718153Recruiting
Using protein tests to diagnose liver cancer types
This trial uses special stains on tumor tissue to find genetic changes in liver cancer cells. It may help doctors better diagnose and classify the type of liver cancer you have.
BolognaAges 18 years+ - NCT06904170RecruitingPhase 2/Phase 3
Immunotherapy with or without liver artery chemo for liver cancer
This trial tests adding a targeted chemo infusion into the liver's main artery to two immunotherapy drugs for liver cancer. It may help patients whose cancer has spread within the liver and can't be removed by surgery.
BordeauxAges 18 years+ - NCT03949231RecruitingPhase 3
Infusion immunotherapy through the liver artery for liver cancer
This trial tests a combination of immune “brakes” medicines (PD-1/PD-L1/CTLA-4) delivered through the liver’s artery, to help treat advanced liver cancer. It may help the immune system attack the cancer more effectively, especially if other local liver treatments aren’t possible or have stopped working.
Guanzhou, GuangdongAges 18–80 - NCT06914648Recruiting
Liver preparation before surgery study for certain liver cancers
This study tests a procedure called portal vein embolization (PVE) to help grow the healthy part of the liver before surgery. It may be an option for people with certain liver cancers who need more healthy liver tissue before their operation.
New Haven, ConnecticutAges 18 years+ - NCT06084234RecruitingPhase 4
National liver cancer screening trial
This trial is testing a new way to screen for liver cancer in people with cirrhosis or chronic hepatitis B. It aims to find cancer earlier so it can be treated more effectively.
Los Angeles, CaliforniaAges 18–85 - NCT06741020RecruitingPhase 1/Phase 2
Chemo and Immunotherapy before Liver Cancer Surgery
This trial tests giving chemotherapy directly into the liver artery (HAIC) combined with immunotherapy before surgery for liver cancer that can be removed but is too large or numerous for standard treatment. The goal is to shrink the tumor and improve surgery results.
Hangzhou, ZhejiangAges 18–75 - NCT07776080RecruitingPhase 2
Immunotherapy, targeted therapy, and radiation for liver cancer with portal vein clot
This trial combines two immunotherapy drugs with a targeted therapy, radiation, and a liver-directed chemotherapy infusion for liver cancer that has spread to the portal vein (the main blood vessel to the liver). The goal is to see if this combination can shrink tumors and help people live longer.
Wuhan, HubeiAges 18–75 - NCT06658782Recruiting
MRI vs ultrasound for liver cancer detection in high-risk people
This trial compares two types of scans to see which detects liver cancer better in people at high risk. You would receive either an MRI with contrast or an ultrasound every 6 months to monitor for liver cancer.
Oxford, OxonAges 18 years+ - NCT07337421RecruitingPhase 2
Chemo infusion after liver cancer surgery to lower recurrence risk
This trial tests whether a targeted chemotherapy infusion directly into the liver's main artery (HAIC) after surgery can prevent liver cancer from coming back. It is for people with certain high-risk features, like a large tumor or cancer in blood vessels, who have had their tumor completely removed.
Yangzhou, JiangsuAges 18–75 - NCT07062055RecruitingPhase 2
Combination therapy for advanced liver cancer that has spread
This trial tests a combination of liver-directed treatments and immunotherapy with a targeted drug for people whose liver cancer has spread to a few other organs. It aims to shrink tumors and improve outcomes.
Jinan, ShandongAges 18–70 - NCT06632717RecruitingPhase 2
Chemo through liver artery with lipiodol for advanced liver cancer
This trial tests giving chemotherapy directly into the liver artery (HAIC) mixed with a special oil called lipiodol. It may help people with advanced liver cancer that cannot be treated with standard methods or who cannot tolerate them.
TaipeiAges 20 years+ - NCT06742424RecruitingPhase 2
PD-L1 antibody + bevacizumab + liver chemo for advanced liver cancer
This trial tests whether combining a PD-L1 antibody (an immunotherapy) with bevacizumab (a drug that slows blood vessel growth to tumors) and a liver-directed chemotherapy infusion can help people with advanced liver cancer that has spread outside the liver. It is designed for patients who have not previously received these specific treatments.
Chengdu, SichuanAges 18–75 - NCT07070076Recruiting
Y-90 therapy vs chemo infusion for liver cancer
This study compares two liver-directed treatments—radioactive Yttrium-90 beads (SIRT) and a type of chemo infusion directly into the liver (HAIC)—for people whose liver cancer is advanced enough to need treatment but might still be removable with surgery. The goal is to see which approach can shrink the tumor best before surgery.
Guangzhou, GuangdongAges 18–75 - NCT06406634RecruitingPhase 2
Cadonilimab, Lenvatinib, and HAIC for Unresectable Liver Cancer
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
Changsha, HunanAges 18–75 - NCT07811687Recruiting
Liver and spleen surgery for liver cancer with cirrhosis
This study tests whether removing part of the liver along with the spleen during laparoscopic (keyhole) surgery helps improve liver function and the immune system in people with liver cancer and cirrhosis. If you qualify, you may have better surgical outcomes and recovery.
Yangzhou, JiangsuAges 18–80 - NCT06796803RecruitingPhase 2/Phase 3
Combination therapy before surgery for liver cancer
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
Harbin, HeilongjiangAges 18–75 - NCT07429864Recruiting
Bulevirtide for hepatitis D: bile acids and gut bacteria
This study looks at how Bulevirtide, a treatment for hepatitis D, affects bile acids and gut bacteria. It may help patients with chronic HDV and stable liver disease who are already on HBV therapy.
RomaAges 18 years+ - NCT07560488RecruitingPhase 2
Immunotherapy and Chemotherapy Combination for Advanced Liver Cancer
This trial tests a combination of four treatments (two immunotherapy drugs, a blood-vessel-blocking drug, and chemotherapy delivered directly to the liver) to shrink unresectable (inoperable) advanced liver cancer and potentially make it removable by surgery. The goal is to help patients who have never had cancer treatment before.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT05286814RecruitingPhase 2
Pump-delivered therapy plus chemo for liver-metastatic cancers
This phase 2 study tests a liver-targeted medicine delivered through a special implanted pump, combined with standard chemo, for cancers that spread mainly to the liver. It may help control tumor growth in the liver and improve outcomes compared with standard treatment alone.
Bethesda, MarylandAges 18–120 - NCT06777017Recruiting
Can liver stiffness predict cancer return after ablation?
This trial studies if measuring liver and spleen stiffness can help predict the risk of liver cancer coming back after radiofrequency ablation (RFA), a treatment that uses heat to destroy tumors. It aims to improve follow-up care for people with chronic liver disease and early-stage liver cancer.
BolognaAges 18 years+
Hear when a new Hepatic Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatic carcinoma?
- Yes. Clin2 currently lists 51 recruiting hepatic carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatic carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatic carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.